- Home
- MGNX vs EUDA Comparison
MGNX vs EUDA Comparison
Compare MGNX & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- EUDA
- Stock Information
- Founded
- MGNX 2000
- EUDA 2021
- Country
- MGNX United States
- EUDA Singapore
- Employees
- MGNX N/A
- EUDA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- EUDA Blank Checks
- Sector
- MGNX Health Care
- EUDA Finance
- Exchange
- MGNX Nasdaq
- EUDA Nasdaq
- Market Cap
- MGNX 99.7M
- EUDA 111.5M
- IPO Year
- MGNX 2013
- EUDA N/A
- Fundamental
- Price
- MGNX $1.53
- EUDA $1.05
- Analyst Decision
- MGNX Hold
- EUDA
- Analyst Count
- MGNX 6
- EUDA 0
- Target Price
- MGNX $3.20
- EUDA N/A
- AVG Volume (30 Days)
- MGNX 1.0M
- EUDA 159.9K
- Earning Date
- MGNX 11-04-2025
- EUDA 01-01-0001
- Dividend Yield
- MGNX N/A
- EUDA N/A
- EPS Growth
- MGNX N/A
- EUDA N/A
- EPS
- MGNX N/A
- EUDA N/A
- Revenue
- MGNX $165,495,000.00
- EUDA $4,011,005.00
- Revenue This Year
- MGNX N/A
- EUDA $212.19
- Revenue Next Year
- MGNX N/A
- EUDA $254.35
- P/E Ratio
- MGNX N/A
- EUDA N/A
- Revenue Growth
- MGNX 303.47
- EUDA 8.22
- 52 Week Low
- MGNX $0.99
- EUDA $1.03
- 52 Week High
- MGNX $5.10
- EUDA $6.30
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- EUDA 21.58
- Support Level
- MGNX $1.46
- EUDA $1.03
- Resistance Level
- MGNX $1.77
- EUDA $1.70
- Average True Range (ATR)
- MGNX 0.15
- EUDA 0.25
- MACD
- MGNX -0.04
- EUDA -0.04
- Stochastic Oscillator
- MGNX 9.21
- EUDA 1.19
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.